Novel Bifunctional Natriuretic Peptides as Potential Therapeutics
Key result
The chimeric peptide CD-NP acts as a partial agonist for NPR-A while maintaining NPR-B activation, and specific mutations in the CNP ring convert it to a full NPR-A agonist.
Population
Human embryonic kidney 293 cells stably expressing rat or human NPR-A or NPR-B
Comparison
CD-NP and its variants vs Endogenous natriuretic peptides and DNP
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
May guide design of dual NPR agonists for cardiorenal disease; leaves open translation to human efficacy.
Structured PICO
P
Population
Human embryonic kidney 293 cells stably expressing rat or human NPR-A or NPR-B
I
Intervention
CD-NP (chimeric peptide of CNP and DNP tail) and its variants (B-CDNP, CDNP-B)
C
Comparator
Endogenous natriuretic peptides (ANP, BNP, CNP) and DNP
O
Outcome
Receptor activation (cGMP elevation) and binding affinity for NPR-A, NPR-B, and NPR-Csurrogate
Bifunctional chimeric natriuretic peptides represent a new generation of therapeutics capable of activating both NPR-A and NPR-B, potentially offering advantages in cardiorenal disease.
Cite This Study
Dickey et al. (2008) studied Congestive heart failure. CD-NP and variants vs. CNP, BNP, DNP was evaluated on Receptor activation and binding affinity (NPR-A, NPR-B, NPR-C). The chimeric peptide CD-NP acts as a partial agonist for NPR-A while maintaining NPR-B activation, and specific mutations in the CNP ring convert it to a full NPR-A agonist.